Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2014, Biohit B has already paid €0.72 in dividends. The last payout was in April 2014.

Financials

In the last quarter, Biohit B had revenue of €7.8m and net profit of €1.3m
(EUR) June 2026
YoY
Revenue 7.8m -
Gross profit 3.2m -
Net profit 1.3m -
EBITDA 1.9m -

Fundamentals

Metric Value
Market capitalization
€32.08m
Number of shares
15.21m
52-week high/low
€3.78 - €2.00
Dividends No
Beta
0.56
P/E ratio
10.27
PEG ratio
0.21
P/B ratio
1.98
P/S ratio
1.99

Company profile

Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.

Name
Biohit B
CEO
Jussi Hahtela
Headquarters Helsinki, uu
Finland
Website
IPO
15/01/2019
Employees 47

Ticker symbols

Exchange Symbol
Hel
BIOBV.HE
Helsinki
BIOBV.HE
London
0DRP.L
🍪

Parqet  uses cookies. Learn more